Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
A novel combinatorial treatment option for metastatic uveal melanoma
Dudi Shneor
, Shay Tayeb
, Jacob Pe'er
, Hanna Voropaev
, Maria Gimmelshein
, Nathalie Cassoux
,
Alik Honigman
,
Shahar Frenkel
*
*
Corresponding author for this work
Institute for Medical Research Israel-Canada (IMRIC)
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A novel combinatorial treatment option for metastatic uveal melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Treatment Options
100%
Doxorubicin
100%
Combinational Therapy
100%
Metastatic Uveal Melanoma
100%
Knockdown
60%
Retrovirus
40%
Uveal Melanoma Cells
40%
Recombinant
20%
Hypoxia
20%
Cell Survival
20%
Cell Death
20%
Metastasis
20%
Tumor Cells
20%
Adult Patients
20%
Murine Leukemia Virus
20%
Alkylating Agents
20%
Uveal Melanoma
20%
Caspase-3 Activation
20%
Short Hairpin RNA (shRNA)
20%
Dacarbazine
20%
Systemic Therapy
20%
Cell Mortality
20%
Normoxia
20%
Tumor Chemotherapy
20%
Recombinant Virus
20%
Intraocular Tumor
20%
Fotemustine
20%
Medicine and Dentistry
Doxorubicin
100%
Metastatic Uvea Melanoma
100%
Treatment Option
100%
Dacarbazine
80%
Uvea Melanoma
60%
Melanoma Cell
40%
Retroviridae
40%
Metastatic Carcinoma
20%
Infection
20%
Hypoxia
20%
Tumor Cell
20%
Caspase 3
20%
Cell Death
20%
Antiinfective Agent
20%
Systemic Therapy
20%
Cell Survival
20%
Short Hairpin RNA
20%
Cancer Chemotherapy
20%
Alkylating Antineoplastic Agent
20%
Virus Recombinant
20%
Intraocular Tumor
20%
Fotemustine
20%
Side Effect
20%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
100%
Metastatic Uvea Melanoma
100%
Dacarbazine
80%
Uvea Melanoma
60%
Retrovirus
40%
Caspase 3
20%
Neoplasm
20%
Infection
20%
Chemotherapy
20%
Antiinfective Agent
20%
Hypoxia
20%
Alkylating Agent
20%
Short Hairpin RNA
20%
Fotemustine
20%
Intraocular Tumor
20%
Side Effect
20%
Immunology and Microbiology
Melanoma Cell
100%
Retrovirus
100%
Cell Survival
50%
Caspase
50%
Tumor Cell
50%
Cell Death
50%
Recombinant Virus
50%
Infection
50%
Neuroscience
Uveal Melanoma
100%
Doxorubicin
100%
CREB
80%
Cell Death
20%
Cell Survival
20%
Caspase 3
20%
Small Hairpin RNA
20%
Alkylating Antineoplastic Agent
20%
Virus Recombinant
20%
Dacarbazine
20%
Fotemustine
20%
Side Effect
20%
Biochemistry, Genetics and Molecular Biology
Doxorubicin
100%
CREB
80%
Retrovirus
40%
Cell Survival
20%
Cell Death
20%
Caspase 3
20%
Small Hairpin RNA
20%
Virus Recombinant
20%
Small Interfering RNA
20%